CytoDyn faces substantial doubt about its ability to continue as a going concern.
SEC EDGAR, 2026-10-14: 10-Q — "substantial doubt"
CytoDyn faces substantial doubt about its ability to continue as a going concern.
Company: CytoDyn Inc. (CYDY) Filed: October 14, 2026, 10-Q (Item 1, Note 2) Phrase: "substantial doubt" — "These factors, among others, including the various matters discussed in Note 10, Commitments and Contingencies , raise substantial doubt about the Company’s ability to continue as a going concern." What the filing says: CytoDyn Inc. has an accumulated deficit of approximately $950.4 million as of August 31, 2026, and has reported losses for all periods presented. These conditions, along with other factors, lead to substantial doubt about the company's ability to continue its operations. The company's future is contingent on its ability to secure additional operating capital, complete the development and obtain regulatory approval for its product candidate, leronlimab, maintain outsourced manufacturing, and ultimately generate revenue and achieve profitability. Two ways it goes: A. The company successfully obtains additional operating capital, completes leronlimab development, secures regulatory approval, and achieves commercialization, allowing it to continue as a going concern. B. The company fails to secure necessary funding or regulatory approvals, leading to an inability to continue its operations. Next date: none named Watch: The company's ability to obtain additional operating capital and regulatory approval for leronlimab.